Zacks: Analysts Expect Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 Million
Equities research analysts expect that Agenus Inc (NASDAQ:AGEN) will post sales of $15.58 million for the current quarter, according to Zacks. Two analysts have issued estimates for Agenus’ earnings, with the highest sales estimate coming in at $27.60 million and the lowest estimate coming in at $3.56 million. Agenus reported sales of $5.58 million during the same quarter last year, which indicates a positive year over year growth rate of 179.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, March 8th.
According to Zacks, analysts expect that Agenus will report full-year sales of $15.58 million for the current financial year, with estimates ranging from $38.08 million to $62.10 million. For the next fiscal year, analysts expect that the firm will post sales of $28.53 million per share, with estimates ranging from $21.46 million to $35.60 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $5.91 million. The firm’s quarterly revenue was down 24.4% compared to the same quarter last year.
In related news, insider Karen Valentine sold 8,358 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $3.46, for a total transaction of $28,918.68. Following the completion of the transaction, the insider now directly owns 109,879 shares of the company’s stock, valued at $380,181.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 20,514 shares of company stock valued at $70,978 over the last three months. Insiders own 7.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Agenus by 5.2% during the second quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after purchasing an additional 174,162 shares during the last quarter. Artal Group S.A. boosted its position in Agenus by 25.0% during the third quarter. Artal Group S.A. now owns 2,500,000 shares of the biotechnology company’s stock valued at $11,025,000 after purchasing an additional 500,000 shares during the last quarter. Northern Trust Corp boosted its position in Agenus by 4.1% during the second quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after purchasing an additional 37,239 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Agenus by 12.8% during the third quarter. Candriam Luxembourg S.C.A. now owns 617,700 shares of the biotechnology company’s stock valued at $2,724,000 after purchasing an additional 70,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in Agenus by 11.4% during the second quarter. Wells Fargo & Company MN now owns 520,142 shares of the biotechnology company’s stock valued at $2,033,000 after purchasing an additional 53,343 shares during the last quarter. 37.89% of the stock is owned by hedge funds and other institutional investors.
Agenus (NASDAQ AGEN) traded down $0.09 during mid-day trading on Thursday, hitting $3.65. The stock had a trading volume of 652,147 shares, compared to its average volume of 1,412,617. The company has a quick ratio of 1.55, a current ratio of 1.55 and a debt-to-equity ratio of -2.39. The firm has a market capitalization of $325.38, a PE ratio of -3.12 and a beta of 2.11. Agenus has a 52 week low of $3.20 and a 52 week high of $5.45.
Agenus Company Profile
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.